Cargando…

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from the pivotal randomized phase 3 ZUMA-7 study of axicabtagene cilo...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsawy, Mahmoud, Chavez, Julio C., Avivi, Irit, Larouche, Jean-François, Wannesson, Luciano, Cwynarski, Kate, Osman, Keren, Davison, Kelly, Rudzki, Jakob D., Dahiya, Saurabh, Dorritie, Kathleen, Jaglowski, Samantha, Radford, John, Morschhauser, Franck, Cunningham, David, Martin Garcia-Sancho, Alejandro, Tzachanis, Dimitrios, Ulrickson, Matthew L., Karmali, Reem, Kekre, Natasha, Thieblemont, Catherine, Enblad, Gunilla, Dreger, Peter, Malladi, Ram, Joshi, Namita, Wang, Wei-Jhih, Solem, Caitlyn T., Snider, Julia Thornton, Cheng, Paul, To, Christina, Kersten, Marie José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653042/
https://www.ncbi.nlm.nih.gov/pubmed/35839452
http://dx.doi.org/10.1182/blood.2022015478